Clinical Trial Detail

NCT ID NCT03635567
Title Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

cervical squamous cell carcinoma

cervical adenocarcinoma

cervical adenosquamous carcinoma

Therapies

Bevacizumab + Carboplatin + Paclitaxel

Bevacizumab + Cisplatin + Paclitaxel

Carboplatin + Paclitaxel

Cisplatin + Paclitaxel

Cisplatin + Paclitaxel + Pembrolizumab

Carboplatin + Paclitaxel + Pembrolizumab

Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab

Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.